VELCADE

Phase 1/2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Amyloidosis

Conditions

Amyloidosis

Trial Timeline

Jun 1, 2005 → Sep 1, 2009

NCT ID

NCT00298766

About VELCADE

VELCADE is a phase 1/2 stage product being developed by Johnson & Johnson for Amyloidosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00298766. Target conditions include Amyloidosis.

What happened to similar drugs?

0 of 12 similar drugs in Amyloidosis were approved

Approved (0) Terminated (2) Active (10)

🔄NTLA-2001 + PlaceboRegeneron PharmaceuticalsPhase 3

🔄PatisiranAlnylam PharmaceuticalsPhase 3

🔄Nucresiran + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 3

🔄Vutrisiran + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 3

🔄Placebo + PatisiranAlnylam PharmaceuticalsPhase 3

🔄patisiran (ALN-TTR02) + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00298766	Phase 1/2	Completed	Jun 1, 2005	Sep 1, 2009	Amyloidosis

Competing Products

20 competing products in Amyloidosis

See all competitors

Product	Company	Stage	Hype Score
ZN-d5	Zentalis Pharmaceuticals	Phase 1/2	22
ABBV-383 (Etentamig)	AbbVie	Phase 1/2	39
Venetoclax + Dexamethasone + Daratumumab	AbbVie	Phase 1/2	24
Eplontersen Solution for Injection	AstraZeneca	Phase 1	29
Treatment of transthyretin (ATTR) amyloidosis in observational study setting	AstraZeneca	Pre-clinical	33
Carfilzomib + Dexamethasone	Amgen	Phase 1	29
Idelalisib	Gilead Sciences	Phase 2	27
Tafamidis	Pfizer	Pre-clinical	26
Tafamidis	Pfizer	Pre-clinical	30
Fx-1006A	Pfizer	Phase 2	35
tafamidis	Pfizer	Pre-clinical	26
Cyclophosphamide + Dexamethasone + Elotuzumab + Lenalidomide	Bristol Myers Squibb	Phase 2	31
Isatuximab	Bristol Myers Squibb	Phase 2	42
Bortezomib + Cyclophosphamide + Dexamethasone + Isatuximab	Sanofi	Phase 1	33
Bendamustine Hydrochloride + Isatuximab	Sanofi	Phase 2	27
NC-503 (Anti-amyloidotic (AA) Agent)	GSK plc	Phase 2/3	38
NTLA-2001 + Placebo	Regeneron Pharmaceuticals	Phase 3	44
Linvoseltamab	Regeneron Pharmaceuticals	Phase 1/2	39
ALN-TTR01 + Sterile Normal Saline (0.9% NaCl)	Alnylam Pharmaceuticals	Phase 1	26
Patisiran	Alnylam Pharmaceuticals	Phase 3	37